Results 31 to 40 of about 15,755 (201)

Immuno-targeting the multifunctional CD38 using nanobody [PDF]

, 2016
published_or_final_versio
Deng, QW, Hao, Q, Hou, YN, Koch-Nolte, F, Lam, MC, Lee, HC, Li, T, Liu, J, Qi, S, Unger, M, Wang, XW, Xin, D, Zhang, H, Zhang, P, Zhao, YJ   +14 more
core   +1 more source

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma [PDF]

, 2021
The efficacy of daratumumab depends partially on CD38 expression on multiple myeloma (MM) cells. We have previously shown that all-trans retinoic acid (ATRA) upregulates CD38 expression and reverts daratumumab-resistance ex vivo.
Bos, Gerard M.J., Broijl, Annemiek, Frerichs, Kristine A., Kersten, Marie Jose, Klein, Saskia K., Levin, Mark David, Maas-Bosman, Patricia W.C., Minnema, Monique C., Mutis, Tuna, Nijhof, Inger S., Sonneveld, Pieter, Van de Donk, Niels W.C.J., Verkleij, Christie P.M., Zweegman, Sonja   +13 more
core   +4 more sources

CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies

OncoImmunology
In multiple myeloma (MM), the anti-CD38 monoclonal antibody Daratumumab has become essential in the therapeutic arsenal, although very few predictive factors of response to Daratumumab have been identified in clinical studies.
Djamila Chemlal, Camille Pochard, Valentin Jacquier, Angélique Bruyer, Ludovic Gabellier, Léa Fornero, Clément Vempère, Amélie Machura, Guilhem Requirand, Nicolas Robert, Caroline Bret, Guillaume Cartron, Laure Vincent, Hugues de Boussac, Jérôme Moreaux, Charles Herbaux   +15 more
doaj   +1 more source

Daratumumab in untreated newly diagnosed multiple myeloma

Therapeutic Advances in Hematology, 2019
The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies.
Nadine Abdallah, Shaji K. Kumar
doaj   +1 more source

Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study

Haematologica, 2023
Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy ...
Luděk Pour, Monika Szarejko, Jelena Bila, Fredrik H. Schjesvold, Ivan Spicka, Vladimir Maisnar, Artur Jurczyszyn, Zhanet Grudeva-Popova, Roman Hájek, Ganna Usenko, Marcus Thuresson, Stefan Norin, Sara Jarefors, Nicolaas A. Bakker, Paul G. Richardson, Maria-Victoria Mateos   +15 more
doaj   +1 more source

Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma [PDF]

, 2021
Patients with relapsed or refractory multiple myeloma have an immunosuppressive state with upregulation of programmed death receptor-1 on immune effector cells.
Carson, Robin, Cohen, Yael C., Crist, Wendy, Feng, Huaibao, Fu, Jiayu, Garvin, Wendy, Jackson, Carolyn, Lavi, Noa, Lonial, Sagar, Oriol, Albert, San-Miguel, Jesus, Schecter, Jordan, Vlummens, Philip, Wu, Ka Lung, Xie, Hong   +14 more
core   +1 more source

Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation [PDF]

, 2017
Multiple myeloma (MM) has benefited from significant advancements in treatment that have improved outcomes and reduced morbidity. However, the disease remains incurable and is characterized by high rates of drug resistance and relapse.
Calistri, Nicholas L, Cetin, Arif Engin, Kimmerling, Robert John, Manalis, Scott R, Olcum, Selim A., Stevens, Mark M.   +5 more
core   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

The real-world outcomes of multiple myeloma patients treated with daratumumab.

PLoS ONE, 2021
Most patients cannot be included in randomized clinical trials. We report real-world outcomes of all Danish patients with multiple myeloma (MM) treated with daratumumab-based regimens until 1 January 2019.MethodsInformation of 635 patients treated with ...
Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Mette Bøegh Levring, Birgitte Preiss, Carsten Helleberg, Marie Fredslund Breinholt, Emil Hermansen, Lise Mette Rahbek Gjerdrum, Søren Thorgaard Bønløkke, Katrine Nielsen, Eigil Kjeldsen, Katrine Fladeland Iversen, Elena Manuela Teodorescu, Marveh Dokhi, Eva Kurt, Casper Strandholdt, Mette Klarskov Andersen, Annette Juul Vangsted   +17 more
doaj   +1 more source

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz, Winfried Alsdorf, Lisa Leypoldt, Piet Sonnemann, Christoph Schaefers, Jule Artzenroth, Marie Harzer, Abdulaziz Kamili, Leandra Bartke, Leon Cords, Jan Vorwerk, Theo Leitner, Markus Maulhardt, Kerstin Brinkert, Annamaria Brioli, Tim Richardson, Udo Holtick, Stefan M. Hillmann, Hans Salwender, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Ricardo Kosch   +22 more
wiley   +1 more source